Related Experiment Video
Updated: Sep 15, 2025

Visualization of Inflammatory Caspases Induced Proximity in Human Monocyte-Derived Macrophages
Published on: April 6, 2022
Cardiolipin inhibits the non-canonical inflammasome by preventing LPS binding to caspase-4/11
Malvina Pizzuto1,2,3, Mercedes Monteleone4, Sabrina Sofia Burgener4
1Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia. m.pizzuto@uq.edu.au.
Insights
Mitochondrial cardiolipin selectively inhibits caspase-4/11 (CASP4/11) to block lipopolysaccharide (LPS)-induced inflammation. This discovery offers a new tool for studying CASP4/11 and developing treatments for LPS-related diseases.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Caspase-4 and caspase-11 (CASP4/11) are key sensors of bacterial lipopolysaccharide (LPS).
- Existing CASP4/11 inhibitors also affect caspase-1 (CASP1), limiting research and therapeutic applications for LPS-linked diseases.
- There is a need for selective inhibitors to study CASP4/11 functions and develop targeted therapies.
Purpose of the Study:
- To identify a selective inhibitor of CASP4/11 activity.
- To investigate the mechanism of selective inhibition by cardiolipin.
- To evaluate the therapeutic potential of cardiolipin in LPS-induced inflammation.
Main Methods:
- Identification of mitochondrial cardiolipin as a selective inhibitor.
- Biochemical assays to determine cardiolipin's interaction with the CARD domain of CASP4/11.
- In vivo studies to assess the suppression of LPS-induced systemic inflammation.
Main Results:
- Mitochondrial cardiolipin selectively inhibits CASP4/11-dependent cell death and inflammatory cytokine secretion.
- Cardiolipin targets the CARD domain of CASP4/11, preventing LPS binding and activation.
- Cardiolipin effectively suppresses LPS-induced systemic inflammation in vivo without affecting CASP1.
Conclusions:
- Cardiolipin is a novel, selective inhibitor of CASP4/11.
- Cardiolipin provides a valuable tool for studying noncanonical inflammasome pathways.
- Cardiolipin holds potential for treating LPS-associated inflammatory diseases.
Abstract:
Caspase-4 and caspase-11 (CASP4/11) sense bacterial lipopolysaccharide (LPS). Currently available inhibitors of CASP4/11 also block the activity of caspase-1 (CASP1), which restricts their usefulness in the study of CASP4/11 functions, as well as their clinical potential for the treatment of LPS-linked diseases through CASP4/11 inhibition. Here, we identify mitochondrial cardiolipin as a selective inhibitor of CASP4/11-dependent cell death and inflammatory cytokine secretion, without affecting CASP1 function. Cardiolipin targets the CARD domain of CASP4/11, impeding its interaction with LPS to restrain CASP4/11 activation, thereby suppressing LPS-induced systemic inflammation in vivo. By identifying cardiolipin as a selective inhibitor of CASP4/11, we provide an urgently needed tool for studying caspase-4/11 and noncanonical inflammasome functions in inflammatory pathways and LPS-induced pathogenesis.
Related Concept Videos
Formation of Lipopolysaccharides
Caspases
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Mechanism of Filopodia Formation
Their main function is to guide migrating cells during normal tissue morphogenesis or cancer metastasis by recognizing and making initial contacts with the extracellular matrix. However, they can also act as stationary cell anchors or help to establish communication...

